Head-to-head · free
10x Genomics, Inc. vs U.S. Physical Therapy
TXG vs USPH — return on capital, cash generation, margins and balance sheet side by side.
TXG
1 / 7
measures where TXG leads
USPH
6 / 7
measures where USPH leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | TXG · FY2025 | USPH · FY2025 |
|---|---|---|
| Revenue | $642.8M | $781.0M |
| Net income | (43.5M) | $39.6M |
| Revenue growth (yearly, multi-year) | 7.0% | 12.1% |
| Free cash flow | $130.1M | — |
| Free cash flow margin | 20.2% | — |
| Net cash / (debt) | — | — |
| ROIC | — | 6.0% |
| Return on equity | -5.8% | 3.1% |
| Gross margin | 69.1% | 19.2% |
| Operating margin | -17.2% | 10.3% |
| Net debt / EBITDA | 27.61x | 1.16x |
Figures are as reported by each company; latest fiscal year shown.
Where 10x Genomics, Inc.'s cash went (FY2025)
- Capital spending
- $5.9M
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where U.S. Physical Therapy's cash went (FY2025)
- Capital spending
- —
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free